Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Radikal

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Sep 18, 2020 4:30pm

216 Views

Post# 31583684

RE:RE:RE:RE:RE:RE:Radikal

I don't wish the price to go down, management is taking care of that for me. I'd love to make back the money I lost when I cut my losses in my other accounts.

Unofficial sources, that's interesting. Can you provide one? Literally one, and I mean not Kalyteran, or anything from the management or SG.

I've been looking and haven't found anything, as far as I can tell no one cares. Maybe I suck at google IDK. But hey if you can show me SOMEONE who isn't KLY affiliated cares, I might change my tune.

And please if you say anything about inhaled, I'm ignoring it.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security